#Gilead Sciences

The 38th annual AIDS Walk New York supports GMHC and other HIV and AIDS groups. Plus: Don’t miss the Latex Ball!

The CDC had sued drugmaker Gilead Sciences for patent infringement over Truvada and Descovy used as PrEP to prevent HIV.

The battle between the CDC and Gilead over the patent for Truvada and Descovy for HIV prevention is heading to court.

FCAA and AIDSVu collaborate to track philanthropic funding within states, counties and cities targeted by the U.S. plan to end HIV.

Similar declines in PrEP budgets likely hit other HIV clinics that serve uninsured Black, brown and LGBTQ communities. Here’s why.

Broadway legend André De Shields and other HIV advocates appear in the commercial to support modernizing HIV crime laws.

This is an improvement from 36% in 2020, notes this year’s State of HIV Stigma Report and survey from GLAAD.

The U.S. Business Action to End HIV coalition boosts public-private partnerships and spells out six ways companies can fight the epidemic.

A $4.5 million joint effort aims to address health inequities in three cities.

Held in Puerto Rico, #2022USCHA highlighted HIV in Latino populations, language justice, storytelling, music and much more.

Wake Forest University’s Faith Coordinating Center launched the Black Faith and HIV initiative with hopes of building a national movement.

Gilead Sciences, the Morehouse School of Medicine and Xavier University boost HIV care for Black Americans in a COVID-impacted South.

Gilead, ViiV, NMAC, HRC, NBJC, GLAAD and others offer $5.5 million in grants to help community groups respond to monkeypox.

Gilead Sciences’ COMPASS Initiative funds the Transformative Grants to bolster HIV groups in the South.

The massive display marked the AIDS Memorial Quilt’s 35th anniversary and a return to its birthplace. Alas, rain cut the event short.

Several makers of hepatitis C drugs are limiting health care providers’ access to the 340B Drug Pricing Program’s discounts.